Press Release PR9.NET
Home Submit Press Release Search Archives
Press Release
Advanced Search
BROWSE BY CATEGORY

Health Health
Organizations
Dentistry, Education
Insurance, Medicine
Mental, Nutrition
Environmental Health
Resources, Weight Loss

Business Business
Computers Computers
Entertainment Entertainment
Games Games
Home Home
Science Science
Sports Sports
Society Society
Teens Teens
Press Release Category Health - Medicine - visiongain Release Date: December 03, 2004

Anti-Migraine Therapies 2005 B2B Conferences


By visiongain
December 03, 2004
Send SEND Print PRINT Download PDF Version PDF Contact visiongain CONTACT

Attend the visiongain's b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conference's objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs.

PR9.NET December 03, 2004 - London, UK; – Attend the visiongain's b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conference's objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs.

Migraine is the most common neurological condition in the developed world. In the seven major pharmaceutical markets, (US, France, Germany, Italy, Spain, UK and Japan) migraine afflicted more than 74 million people in 2002. It affects 11% of the UK population and is more prevalent than diabetes, epilepsy and asthma combined.

Over the two days, this event will provide a comprehensive focus on the potential for genetic research in the future of migraine treatments and discovery the possibilities for new drugs. Leaders from the Pharmaceutical sector will also investigate the main challenges involved in alternative therapies and the new possibilities for Botox as an anti-migraine treatment. Learn directly from the experts: focused and detailed case studies from industry leaders GSK, Boehringer-Ingelheim; Aradigm. Additional, discover the possible future targets for anti-migraine therapies and learn which are the areas to watch: ensure your company gains its share of the market and the benefit from the new technology available and achieve more efficient drug delivery for your drugs

The ANTI-MIGRAINE THERAPIES CONFERENCE will take place on March 8th & 9th at the Hilton Kensington Hotel, London.

Companies and organisations participating in the conference program:

 Dr. Michael James, Head of Preclinical MRI, Neurology & Gastrointestinal CEDD , GlaxoSmithKline
 Dr. Henry Doods, Head of Pain Research, Boehringer-Ingelheim
 Dr. Stephen Farr, Chief Scientific Officer, Aradigm
 Dr. Chas Bountra, Head, Pain Research, GlaxoSmithKline
 Barry Cohen, Vice President & New Product Development, NovaDel
 Dr. Stephen Silberstein, Director, Jefferson Headache Center
 Dr. Don Penzien, Director & Founder, UMC Head Pain Center
 Dr. Ann Pakalnis, Clinical Associate Professor of Paediatrics & Neurology, Ohio State University & Columbus Children's Hospital

Complementing this conference, is a Pre-conference Interactive Workshop (Thursday 7th March 2005) entitled PRICING AND POSITIONING FOR AN INNOVATIVE ANTI-MIGRAINE TREATMENT which will be led by:

Mr. Christian Schuler, Director, Health Sciences Division, Simon-Kucher & Partners

This pre-conference workshop focuses on pricing and reimbursement environment in the anti-migraine market and value based pricing for a new anti-migraine treatment. With an in-depth analysis of the ideal positioning of an innovative anti-migraine therapy and how to derive optimal prices.

For more information about this event, please visit www.b2b-conferences.com


# # #

Contact Information of visiongain Contact Information of visiongain
Phone +44 020 8767 6711
Website http://www.visiongain.com
E-Mail E-mail Address Protected

About B2B Conferences

B2B Conferences is one of Europe's fastest growing media companies today, basing its knowledge on the raft of management reports and industry news letter that the parent company produces each year. B2B Conferences has built up a solid reputation for putting together high quality business to business event workshops aimed at the corporate community.

These events are unique in that B2B operates on a wholly independent basis, therefore producing conferences that are timely, targeted and at time controversial, giving delegates, speakers and sponsors alike, the opportunity to get a totally unbiased view of their industry.


About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe today. visiongain produce a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Financial markets, the Pharmaceutical, Telecoms industries and the Defence sector.







Recent News Headlines
More Press Releases
Industry Category of Current Press Release
    Copyright © 2004 - 2014 PR9.NET - All rights reserved RSS Feeds Submit Press Release Terms of Service Privacy Policy